Aradigm first quarter total income decreases to $0 here .2 million Aradigm Company today announced financial outcomes for the first quarter and three months ended March 31, 2011. Total revenue was $0.2 million for the 1st quarter of 2011, compared with $4.0 million in revenue for the first quarter of 2010. Revenue for the first quarter of 2010 reflects the receipt of the milestone payment due from Zogenix, Inc. Upon the first U.S. Sale of SUMAVEL DosePro needle-free delivery system for treatment of acute cluster and migraines. Revenue for the initial quarter of 2011 reflects the quarterly royalty payment from Zogenix for SUMAVEL product sales.


.. Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin Aradigm Company today announced that the U.S. The QIDP designation, granted for treatment of non-cystic fibrosis bronchiectasis patients with chronic lung infections with Pseudomonas aeruginosa, can make Pulmaquin eligible to benefit from specific incentives for the development of brand-new antibiotics provided under the Generating Antibiotic Incentives Today Act . These incentives include priority eligibility and review for fast-track status. Further, if ultimately authorized by the FDA, Pulmaquin is qualified to receive an additional five-year expansion of Hatch-Waxman exclusivity. Related StoriesPeople confused about antibiotic resistance, displays WHO surveyNew broad-spectrum antibiotic can eliminate bacteria by punching holes in their membranesShared decision making between doctors and patients useful in fight antibiotic resistanceThe Phase III clinical program for Pulmaquin in non-CF BE consists of two worldwide, double-blind, placebo-controlled pivotal trials that are identical in style aside from a pharmacokinetics sub-research to be conducted in one of the trials.